Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2007 1
2011 1
2012 1
2014 1
2015 1
2017 1
2018 1
2019 1
2020 1
2021 2
2022 1
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
Genetic and Neuroimaging Analysis of SIGMAR1 for Frontotemporal Dementia.
Che XQ, Lin GZ, Liu XH, Wang G, Zhao QH, Ren RJ. Che XQ, et al. J Alzheimers Dis. 2023;95(2):469-475. doi: 10.3233/JAD-221195. J Alzheimers Dis. 2023. PMID: 37545231
However, no SIGMAR1 genotype analysis has been reported in a cohort absent of C9orf72 pathogenic repeat expansions to date. ...For the patient carrying SIGMAR1 variant, a follow-up 3T MR imaging was performed in the study. ...
However, no SIGMAR1 genotype analysis has been reported in a cohort absent of C9orf72 pathogenic repeat expansions to date. ...For th …
Sigma 1 Receptor and Ion Channel Dynamics in Cancer.
Soriani O, Rapetti-Mauss R. Soriani O, et al. Adv Exp Med Biol. 2017;964:63-77. doi: 10.1007/978-3-319-50174-1_6. Adv Exp Med Biol. 2017. PMID: 28315265 Review.
SigmaR1 is a multitasking chaperone protein which has mainly been studied in CNS physiological and pathophysiological processes such as pain, memory, neurodegenerative diseases (amyotrophic lateral sclerosis , Parkinson's and Alzheimer's diseases, retinal neu …
SigmaR1 is a multitasking chaperone protein which has mainly been studied in CNS physiological and pathophysiological processes such …
Alzheimer's Disease and Neurotransmission Gene Variants: Focus on Their Effects on Psychiatric Comorbidities and Inflammatory Parameters.
Porcelli S, Calabrò M, Crisafulli C, Politis A, Liappas I, Albani D, Raimondi I, Forloni G, Benedetti F, Papadimitriou GN, Serretti A. Porcelli S, et al. Neuropsychobiology. 2019;78(2):79-85. doi: 10.1159/000497164. Epub 2019 May 16. Neuropsychobiology. 2019. PMID: 31096213
BACKGROUND: Alzheimer's disease (AD) is a neurodegenerative disorder accounting for 60-70% of dementia cases. Genetic origin accounts for 49-79% of disease risk. This paper aims to investigate the association of 17 polymorphisms within 7 genes involved …
BACKGROUND: Alzheimer's disease (AD) is a neurodegenerative disorder accounting for 60-70% of dementia cases. Genetic o …
Sigma receptor type 1 gene variation in a group of Polish patients with Alzheimer's disease and mild cognitive impairment.
Maruszak A, Safranow K, Gacia M, Gabryelewicz T, Słowik A, Styczyńska M, Pepłońska B, Golan MP, Zekanowski C, Barcikowska M. Maruszak A, et al. Dement Geriatr Cogn Disord. 2007;23(6):432-8. doi: 10.1159/000101990. Epub 2007 Apr 23. Dement Geriatr Cogn Disord. 2007. PMID: 17457031
The sigma-1 receptor (SIGMAR1) is a subtype of a nonopioid sigma receptor family and is implicated in numerous functions connected with Alzheimer's disease (AD). ...Multivariate logistic regression analysis showed no interaction between the APOE4 and …
The sigma-1 receptor (SIGMAR1) is a subtype of a nonopioid sigma receptor family and is implicated in numerous functions connected wi …
The involvement of the sigma-1 receptor in neurodegeneration and neurorestoration.
Ruscher K, Wieloch T. Ruscher K, et al. J Pharmacol Sci. 2015 Jan;127(1):30-5. doi: 10.1016/j.jphs.2014.11.011. Epub 2014 Dec 9. J Pharmacol Sci. 2015. PMID: 25704015 Free article. Review.
Neuroprotection appears to be due to inhibition of cellular Ca(2+) toxicity and/or inflammation, and neurorestoration may include balancing abberant neurotransmission or stimulation of synaptogenesis, thus remodelling brain connectivity. Single nucleotide polymorphisms and mutati …
Neuroprotection appears to be due to inhibition of cellular Ca(2+) toxicity and/or inflammation, and neurorestoration may include balancing …
Emerging Benefits: Pathophysiological Functions and Target Drugs of the Sigma-1 Receptor in Neurodegenerative Diseases.
Wu NH, Ye Y, Wan BB, Yu YD, Liu C, Chen QJ. Wu NH, et al. Mol Neurobiol. 2021 Nov;58(11):5649-5666. doi: 10.1007/s12035-021-02524-5. Epub 2021 Aug 12. Mol Neurobiol. 2021. PMID: 34383254 Review.
The sigma-1 receptor (Sig-1R) is encoded by the SIGMAR1 gene and is a nonopioid transmembrane receptor located in the mitochondrial-associated endoplasmic reticulum membrane (MAM). ...Based on its neuroprotective effects, Sig-1R has now become a breakthrough target for all …
The sigma-1 receptor (Sig-1R) is encoded by the SIGMAR1 gene and is a nonopioid transmembrane receptor located in the mitochondrial-a …
Genetic polymorphisms in sigma-1 receptor and apolipoprotein E interact to influence the severity of Alzheimer's disease.
Huang Y, Zheng L, Halliday G, Dobson-Stone C, Wang Y, Tang HD, Cao L, Deng YL, Wang G, Zhang YM, Wang JH, Hallupp M, Kwok J, Chen SD. Huang Y, et al. Curr Alzheimer Res. 2011 Nov;8(7):765-70. doi: 10.2174/156720511797633232. Curr Alzheimer Res. 2011. PMID: 21605063
Apolipoprotein E (APOE) epsilon4 allele and sigma-1 receptor (SIGMAR1) c.5C (Q2P) polymorphisms have been acknowledged as risk factors for developing Alzheimer's disease (AD). ...Associations between SIGMAR1 Q2P and APOE genotypes and disease …
Apolipoprotein E (APOE) epsilon4 allele and sigma-1 receptor (SIGMAR1) c.5C (Q2P) polymorphisms have been acknowledged as risk factor …
Effect of Fluvoxamine on Amyloid-β Peptide Generation and Memory.
Kim WS, Fu Y, Dobson-Stone C, Hsiao JT, Shang K, Hallupp M, Schofield PR, Garner B, Karl T, Kwok JBJ. Kim WS, et al. J Alzheimers Dis. 2018;62(4):1777-1787. doi: 10.3233/JAD-171001. J Alzheimers Dis. 2018. PMID: 29614681
Alzheimer's disease is characterized by abnormal amyloid-beta (Abeta) peptide accumulation beginning decades before symptom onset. ...We firstly investigated the impact of SIGMAR1 on AbetaPP processing, and found that overexpression and knockdown of …
Alzheimer's disease is characterized by abnormal amyloid-beta (Abeta) peptide accumulation beginning decades before sym …
Association between a variant of the sigma-1 receptor gene and Alzheimer's disease.
Fehér Á, Juhász A, László A, Kálmán J Jr, Pákáski M, Kálmán J, Janka Z. Fehér Á, et al. Neurosci Lett. 2012 May 31;517(2):136-9. doi: 10.1016/j.neulet.2012.04.046. Epub 2012 Apr 25. Neurosci Lett. 2012. PMID: 22561649
Alzheimer's disease (AD) is a progressive neurodegenerative disorder with complex etiology and strong genetic predisposition. A number of investigations support the possible involvement of sigma non-opioid intracellular receptor 1 (SIGMAR1) in the path …
Alzheimer's disease (AD) is a progressive neurodegenerative disorder with complex etiology and strong genetic predispos …
A precision medicine framework using artificial intelligence for the identification and confirmation of genomic biomarkers of response to an Alzheimer's disease therapy: Analysis of the blarcamesine (ANAVEX2-73) Phase 2a clinical study.
Hampel H, Williams C, Etcheto A, Goodsaid F, Parmentier F, Sallantin J, Kaufmann WE, Missling CU, Afshar M. Hampel H, et al. Alzheimers Dement (N Y). 2020 Apr 19;6(1):e12013. doi: 10.1002/trc2.12013. eCollection 2020. Alzheimers Dement (N Y). 2020. PMID: 32318621 Free PMC article.
INTRODUCTION: The search for drugs to treat Alzheimer's disease (AD) has failed to yield effective therapies. Here we report the first genome-wide search for biomarkers associated with therapeutic response in AD. ...METHODS: Safety, clinical features, pharmac …
INTRODUCTION: The search for drugs to treat Alzheimer's disease (AD) has failed to yield effective therapies. Here we r …
14 results